Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 1/2012

01-03-2012 | Review

Targeting pattern recognition receptors in cancer immunotherapy

Authors: Nadège Goutagny, Yann Estornes, Uzma Hasan, Serge Lebecque, Christophe Caux

Published in: Targeted Oncology | Issue 1/2012

Login to get access

Abstract

Pattern recognition receptors (PRRs) are known for many years for their role in the recognition of microbial products and the subsequent activation of the immune system. The 2011 Nobel Prize for medicine indeed rewarded J. Hoffmann/B. Beutler and R. Steinman for their revolutionary findings concerning the activation of the immune system, thus stressing the significance of understanding the mechanisms of activation of the innate immunity. Such immunostimulatory activities are of major interest in the context of cancer to induce long-term antitumoral responses. Ligands for the toll-like receptors (TLRs), a well-known family of PRR, have been shown to have antitumoral activities in several cancers. Those ligands are now undergoing extensive clinical investigations both as immunostimulant molecules and as adjuvant along with vaccines. However, when considering the use of these ligands in tumor therapy, one shall consider the potential effect on the tumor cells themselves as well as on the entire organism. Recent data indeed demonstrate that TLR activation in tumor cells could trigger both pro- or antitumoral effect depending on the context. This review discusses this balance between the intrinsic activation of PRR in tumor cells and the extrinsic microenvironment activation in term of overall effect of PRR ligands on tumor development. We review recent advances in the field and underline appealing prospects for clinical development of PRR agonists in the light of our current knowledge on their expression and activation.
Literature
1.
2.
Coley WB (1991) The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 262:3–11PubMed
3.
Goutagny N, Fitzgerald KA (2006) Pattern recognition receptors: an update. Expert Rev Clin Immunol 2:569–583PubMedCrossRef
4.
5.
Barber GN (2011) Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses. Curr Opin Immunol 23:10–20PubMedCrossRef
6.
Barton GM, Kagan JC (2009) A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol 9:535–542PubMedCrossRef
7.
Kono H, Rock KL (2008) How dying cells alert the immune system to danger. Nat Rev Immunol 8:279–289PubMedCrossRef
8.
Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T et al (2002) Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168:4531–4537PubMed
9.
Zhang Z, Kim T, Bao M, Facchinetti V, Jung SY, Ghaffari AA et al (2011) DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells. Immunity 34:866–878PubMedCrossRef
10.
Ishikawa H, Ma Z, Barber GN (2009) STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461:788–792PubMedCrossRef
11.
Bryant C, Fitzgerald KA (2009) Molecular mechanisms involved in inflammasome activation. Trends Cell Biol 19:455–464PubMedCrossRef
12.
Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K et al (2005) Cell type-specific involvement of RIG-I in antiviral response. Immunity 23:19–28PubMedCrossRef
13.
Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M et al (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5:730–737PubMedCrossRef
14.
Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL et al (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9:847–856PubMedCrossRef
15.
Kanneganti TD, Ozoren N, Body-Malapel M, Amer A, Park JH, Franchi L et al (2006) Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440:233–236PubMedCrossRef
16.
Kanneganti TD, Body-Malapel M, Amer A, Park JH, Whitfield J, Franchi L et al (2006) Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J Biol Chem 281:36560–36568PubMedCrossRef
17.
Mariathasan S, Newton K, Monack DM, Vucic D, French DM, Lee WP et al (2004) Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430:213–218PubMedCrossRef
18.
Mariathasan S, Weiss DS, Newton K, McBride J, O’Rourke K, Roose-Girma M et al (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440:228–232PubMedCrossRef
19.
Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241PubMedCrossRef
20.
Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES (2009) AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458:509–513PubMedCrossRef
21.
Kim S, Bauernfeind F, Ablasser A, Hartmann G, Fitzgerald KA, Latz E et al (2010) Listeria monocytogenes is sensed by the NLRP3 and AIM2 inflammasome. Eur J Immunol 40:1545–1551PubMedCrossRef
22.
Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L et al (2010) The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 11:395–402PubMedCrossRef
23.
Roberts TL, Idris A, Dunn JA, Kelly GM, Burnton CM, Hodgson S et al (2009) HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 323:1057–1060PubMedCrossRef
24.
Petrilli V, Dostert C, Muruve DA, Tschopp J (2007) The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 19:615–622PubMedCrossRef
25.
Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987–995PubMedCrossRef
26.
Anderson KV, Bokla L, Nusslein-Volhard C (1985) Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell 42:791–798PubMedCrossRef
27.
28.
Medzhitov R, Preston-Hurlburt P, Janeway CA Jr (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388:394–397PubMedCrossRef
29.
Yarovinsky F, Zhang D, Andersen JF, Bannenberg GL, Serhan CN, Hayden MS et al (2005) TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 308:1626–1629PubMedCrossRef
30.
Zhang Z, Schluesener HJ (2006) Mammalian toll-like receptors: from endogenous ligands to tissue regeneration. Cell Mol Life Sci 63:2901–2907PubMedCrossRef
31.
Hayashi F, Means TK, Luster AD (2003) Toll-like receptors stimulate human neutrophil function. Blood 102:2660–2669PubMedCrossRef
32.
Muzio M, Bosisio D, Polentarutti N, D’Amico G, Stoppacciaro A, Mancinelli R et al (2000) Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 164:5998–6004PubMed
33.
Komiya A, Nagase H, Okugawa S, Ota Y, Suzukawa M, Kawakami A et al (2006) Expression and function of toll-like receptors in human basophils. Int Arch Allergy Immunol 140(Suppl 1):23–27PubMedCrossRef
34.
Mansson A, Cardell LO (2009) Role of atopic status in Toll-like receptor (TLR)7- and TLR9-mediated activation of human eosinophils. J Leukoc Biol 85:719–727PubMedCrossRef
35.
Genestier L, Taillardet M, Mondiere P, Gheit H, Bella C, Defrance T (2007) TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J Immunol 178:7779–7786PubMed
36.
Pan ZK, Fisher C, Li JD, Jiang Y, Huang S, Chen LY (2011) Bacterial LPS up-regulated TLR3 expression is critical for antiviral response in human monocytes: evidence for negative regulation by CYLD. Int Immunol 23:357–364PubMedCrossRef
37.
Hasan UA, Trinchieri G, Vlach J (2005) Toll-like receptor signaling stimulates cell cycle entry and progression in fibroblasts. J Biol Chem 280:20620–20627PubMedCrossRef
38.
Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A (2001) Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 31:3388–3393PubMedCrossRef
39.
Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F et al (2001) Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194:863–869PubMedCrossRef
40.
Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E et al (2003) LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 198:1043–1055PubMedCrossRef
41.
Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T (2003) TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol 4:161–167PubMedCrossRef
42.
Honda K, Yanai H, Mizutani T, Negishi H, Shimada N, Suzuki N et al (2004) Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc Natl Acad Sci USA 101:15416–15421PubMedCrossRef
43.
Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M et al (2004) Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 5:1061–1068PubMedCrossRef
44.
Hasan UA, Caux C, Perrot I, Doffin AC, Menetrier-Caux C, Trinchieri G et al (2007) Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. Proc Natl Acad Sci USA 104:8047–8052PubMedCrossRef
45.
Kollisch G, Kalali BN, Voelcker V, Wallich R, Behrendt H, Ring J et al (2005) Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology 114:531–541PubMedCrossRef
46.
Gribar SC, Anand RJ, Sodhi CP, Hackam DJ (2008) The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation. J Leukoc Biol 83:493–498PubMedCrossRef
47.
Grote K, Schuett H, Schieffer B (2011) Toll-like receptors in angiogenesis. Sci World J 11:981–991CrossRef
48.
Hwa CH, Bae YC, Jung JS (2006) Role of toll-like receptors on human adipose-derived stromal cells. Stem Cells 24:2744–2752CrossRef
49.
Bsibsi M, Ravid R, Gveric D, van Noort JM (2002) Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 61:1013–1021PubMed
50.
Dupaul-Chicoine J, Yeretssian G, Doiron K, Bergstrom KS, McIntire CR, LeBlanc PM et al (2010) Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 32:367–378PubMedCrossRef
51.
Salcedo R, Worschech A, Cardone M, Jones Y, Gyulai Z, Dai RM et al (2010) MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 207:1625–1636PubMedCrossRef
52.
Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118:229–241PubMedCrossRef
53.
El-Omar EM, Ng MT, Hold GL (2008) Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene 27:244–252PubMedCrossRef
54.
Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H (2008) TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27:218–224PubMedCrossRef
55.
Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E et al (2006) Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 4:437–447PubMedCrossRef
56.
Brignole C, Marimpietri D, Di PD, Perri P, Morandi F, Pastorino F et al (2010) Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma. Cancer Res 70:9816–9826PubMedCrossRef
57.
Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V et al (2007) TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178:3186–3197PubMed
58.
Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W et al (2010) Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci 101:1059–1066PubMedCrossRef
59.
Salaun B, Zitvogel L, Asselin-Paturel C, Morel Y, Chemin K, Dubois C et al (2011) TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res 71:1607–1614PubMedCrossRef
60.
Menendez D, Shatz M, Azzam K, Garantziotis S, Fessler MB, Resnick MA (2011) The Toll-like receptor gene family is integrated into human DNA damage and p53 networks. PLoS Genet 7:e1001360PubMedCrossRef
61.
Kang DC, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB (2002) mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci USA 99:637–642PubMedCrossRef
62.
Linder P (2006) Dead-box proteins: a family affair—active and passive players in RNP-remodeling. Nucleic Acids Res 34:4168–4180PubMedCrossRef
63.
Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H et al (2005) IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 6:981–988PubMedCrossRef
64.
Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R et al (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437:1167–1172PubMedCrossRef
65.
Seth RB, Sun L, Ea CK, Chen ZJ (2005) Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122:669–682PubMedCrossRef
66.
Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB (2005) VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 19:727–740PubMedCrossRef
67.
Rothenfusser S, Goutagny N, DiPerna G, Gong M, Monks BG, Schoenemeyer A et al (2005) The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J Immunol 175:5260–5268PubMed
68.
Satoh T, Kato H, Kumagai Y, Yoneyama M, Sato S, Matsushita K et al (2010) LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. Proc Natl Acad Sci USA 107:1512–1517PubMedCrossRef
69.
Venkataraman T, Valdes M, Elsby R, Kakuta S, Caceres G, Saijo S et al (2007) Loss of DExD/H box RNA helicase LGP2 manifests disparate antiviral responses. J Immunol 178:6444–6455PubMed
70.
Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F et al (2006) RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314:997–1001PubMedCrossRef
71.
Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H et al (2006) 5′-Triphosphate RNA is the ligand for RIG-I. Science 314:994–997PubMedCrossRef
72.
Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K et al (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441:101–105PubMedCrossRef
73.
Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K et al (2008) Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 205:1601–1610PubMedCrossRef
74.
Zhang NN, Shen SH, Jiang LJ, Zhang W, Zhang HX, Sun YP et al (2008) RIG-I plays a critical role in negatively regulating granulocytic proliferation. Proc Natl Acad Sci USA 105:10553–10558PubMedCrossRef
75.
Kim T, Pazhoor S, Bao M, Zhang Z, Hanabuchi S, Facchinetti V et al (2010) Aspartate-glutamate-alanine-histidine box motif (DEAH)/RNA helicase A helicases sense microbial DNA in human plasmacytoid dendritic cells. Proc Natl Acad Sci USA 107:15181–15186PubMedCrossRef
76.
Jung A, Kato H, Kumagai Y, Kumar H, Kawai T, Takeuchi O et al (2008) Lymphocytoid choriomeningitis virus activates plasmacytoid dendritic cells and induces a cytotoxic T-cell response via MyD88. J Virol 82:196–206PubMedCrossRef
77.
Hochrein H, Schlatter B, O’Keeffe M, Wagner C, Schmitz F, Schiemann M et al (2004) Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways. Proc Natl Acad Sci USA 101:11416–11421PubMedCrossRef
78.
Hokeness-Antonelli KL, Crane MJ, Dragoi AM, Chu WM, Salazar-Mather TP (2007) IFN-alphabeta-mediated inflammatory responses and antiviral defense in liver is TLR9-independent but MyD88-dependent during murine cytomegalovirus infection. J Immunol 179:6176–6183PubMed
79.
Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H et al (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301:640–643PubMedCrossRef
80.
Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413:732–738PubMedCrossRef
81.
Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K et al (2002) Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 169:6668–6672PubMed
82.
Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K et al (2005) Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 175:2851–2858PubMed
83.
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964PubMedCrossRef
84.
Balenga NA, Balenga NA (2007) Human TLR11 gene is repressed due to its probable interaction with profilin expressed in human. Med Hypotheses 68:456PubMedCrossRef
85.
Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA (2001) Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 75:10730–10737PubMedCrossRef
86.
Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA et al (2000) Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1:398–401PubMedCrossRef
87.
Georgel P, Jiang Z, Kunz S, Janssen E, Mols J, Hoebe K et al (2007) Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway. Virology 362:304–313PubMedCrossRef
88.
Rassa JC, Meyers JL, Zhang Y, Kudaravalli R, Ross SR (2002) Murine retroviruses activate B cells via interaction with toll-like receptor 4. Proc Natl Acad Sci USA 99:2281–2286PubMedCrossRef
89.
Rolland A, Jouvin-Marche E, Viret C, Faure M, Perron H, Marche PN (2006) The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses. J Immunol 176:7636–7644PubMed
90.
Cavaleiro R, Brunn GJ, Albuquerque AS, Victorino RM, Platt JL, Sousa AE (2007) Monocyte-mediated T cell suppression by HIV-2 envelope proteins. Eur J Immunol 37:3435–3444PubMedCrossRef
91.
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050–1059PubMedCrossRef
92.
Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R (2008) TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol 9:361–368PubMedCrossRef
93.
Lindstrom S, Hunter DJ, Gronberg H, Stattin P, Wiklund F, Xu J et al (2010) Sequence variants in the TLR4 and TLR6-1-10 genes and prostate cancer risk. Results based on pooled analysis from three independent studies. Cancer Epidemiol Biomarkers Prev 19:873–876PubMedCrossRef
94.
Pimentel-Nunes P, Soares JB, Roncon-Albuquerque R Jr, Dinis-Ribeiro M, Leite-Moreira AF (2010) Toll-like receptors as therapeutic targets in gastrointestinal diseases. Expert Opin Ther Targets 14:347–368PubMedCrossRef
95.
Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S et al (2006) TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66:3859–3868PubMedCrossRef
96.
Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH et al (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65:5009–5014PubMedCrossRef
97.
Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A et al (2009) Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 69:3105–3113PubMedCrossRef
98.
Huang B, Zhao J, Shen S, Li H, He KL, Shen GX et al (2007) Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res 67:4346–4352PubMedCrossRef
99.
Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D (2011) Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res 71:2466–2475PubMedCrossRef
100.
Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB et al (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 325:1205–1209PubMedCrossRef
101.
Khanna OP, Son DL, Mazer H, Read J, Nugent D, Cottone R et al (1990) Multicenter study of superficial bladder cancer treated with intravesical bacillus Calmette-Guerin or adriamycin. Urology 35:101–108PubMedCrossRef
102.
Shelley MD, Mason MD, Kynaston H (2010) Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev 36:195–205PubMedCrossRef
103.
Dovedi SJ, Davies BR (2009) Emerging targeted therapies for bladder cancer: a disease waiting for a drug. Cancer Metastasis Rev 28:355–367PubMedCrossRef
104.
Alexandroff AB, Jackson AM, O’Donnell MA, James K (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353:1689–1694PubMedCrossRef
105.
Ponticiello A, Perna F, Maione S, Stradolini M, Testa G, Terrazzano G et al (2004) Analysis of local T lymphocyte subsets upon stimulation with intravesical BCG: a model to study tuberculosis immunity. Respir Med 98:509–514PubMedCrossRef
106.
Higuchi T, Shimizu M, Owaki A, Takahashi M, Shinya E, Nishimura T et al (2009) A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth. Cancer Immunol Immunother 58:1245–1255PubMedCrossRef
107.
Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A et al (2000) Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immun 68:6883–6890PubMedCrossRef
108.
von Meyenn F, Schaefer M, Weighardt H, Bauer S, Kirschning CJ, Wagner H et al (2006) Toll-like receptor 9 contributes to recognition of Mycobacterium bovis bacillus Calmette-Guerin by Flt3-ligand generated dendritic cells. Immunobiology 211:557–565CrossRef
109.
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54–61PubMedCrossRef
110.
Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C et al (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15:1170–1178PubMedCrossRef
111.
Zitvogel L, Kepp O, Kroemer G (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8:151–160PubMedCrossRef
112.
Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J et al (2011) Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 71:4821–4833PubMedCrossRef
113.
Giannini SL, Hanon E, Moris P, Van MM, Morel S, Dessy F et al (2006) Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24:5937–5949PubMedCrossRef
114.
Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H et al (2009) AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 183:6186–6197PubMedCrossRef
115.
Cluff CW (2009) Monophosphoryl lipid A (PML) as an adjuvant for anti-cancer vaccines: clinical results. In: Jeannin JF (ed) Lipid A in cancer therapy. Landes Bioscience, Austin
116.
Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E et al (2004) Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 172:3289–3296PubMed
117.
Kruit WH (2008) Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectabke and progressive metastatic cutaneous melanoma: a randomized open-label phase II study of the EORTC Melanoma Group (16032-18031). J Clin Oncol 26:9065
118.
Butts C, Maksymiuk A, Goss G, Soulieres D, Marshall E, Cormier Y et al (2011) Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 137(9):1337–1342PubMedCrossRef
119.
Miles DW, Towlson KE, Graham R, Reddish M, Longenecker BM, Taylor-Papadimitriou J et al (1996) A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer 74:1292–1296PubMedCrossRef
120.
Miles D, Roche H, Martin M, Perren TJ, Cameron DA, Glaspy J et al (2011) Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 16(8):1092–1100PubMedCrossRef
121.
Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S (2008) Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother 31:849–857PubMedCrossRef
122.
Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S et al (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:345–350PubMedCrossRef
123.
Sarma PS, Shiu G, Neubauer RH, Baron S, Huebner RJ (1969) Virus-induced sarcoma of mice: inhibition by a synthetic polyribonucleotide complex. Proc Natl Acad Sci USA 62:1046–1051PubMedCrossRef
124.
Levy HB, Law LW, Rabson AS (1969) Inhibition of tumor growth by polyinosinic-polycytidylic acid. Proc Natl Acad Sci USA 62:357–361PubMedCrossRef
125.
Yu M, Lam J, Rada B, Leto TL, Levine SJ (2011) Double-stranded RNA induces shedding of the 34-kDa soluble TNFR1 from human airway epithelial cells via TLR3-TRIF-RIP1-dependent signaling: roles for dual oxidase 2- and caspase-dependent pathways. J Immunol 186:1180–1188PubMedCrossRef
126.
Whitson JM, Noonan EJ, Pookot D, Place RF, Dahiya R (2009) Double stranded-RNA-mediated activation of P21 gene induced apoptosis and cell cycle arrest in renal cell carcinoma. Int J Cancer 125:446–452PubMedCrossRef
127.
Weber A, Kirejczyk Z, Besch R, Potthoff S, Leverkus M, Hacker G (2010) Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells. Cell Death Differ 17:942–951PubMedCrossRef
128.
Taura M, Fukuda R, Suico MA, Eguma A, Koga T, Shuto T et al (2010) TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis. Cancer Sci 101:1610–1617PubMedCrossRef
129.
Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P (2007) Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 13:4565–4574PubMedCrossRef
130.
Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T (2006) TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 176:4894–4901PubMed
131.
Paone A, Starace D, Galli R, Padula F, De CP, Filippini A et al (2008) Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 29:1334–1342PubMedCrossRef
132.
Morikawa T, Sugiyama A, Kume H, Ota S, Kashima T, Tomita K et al (2007) Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin Cancer Res 13:5703–5709PubMedCrossRef
133.
Jiang Q, Wei H, Tian Z (2008) Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway. BMC Cancer 8:12PubMedCrossRef
134.
Friboulet L, Pioche-Durieu C, Rodriguez S, Valent A, Souquere S, Ripoche H et al (2008) Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to Toll-like receptor 3-mediated apoptosis. Neoplasia 10:1183–1194PubMed
135.
Friboulet L, Gourzones C, Tsao SW, Morel Y, Paturel C, Temam S et al (2010) Poly(I:C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cells. BMC Cancer 10:327PubMedCrossRef
136.
Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M et al (2011) cIAPs block ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 43:449–463PubMedCrossRef
137.
Chiron D, Pellat-Deceunynck C, Amiot M, Bataille R, Jego G (2009) TLR3 ligand induces NF-κB activation and various fates of multiple myeloma cells depending on IFN-κ production. J Immunol 182:4471–4478PubMedCrossRef
138.
Pries R, Hogrefe L, Xie L, Frenzel H, Brocks C, Ditz C et al (2008) Induction of c-Myc-dependent cell proliferation through toll-like receptor 3 in head and neck cancer. Int J Mol Med 21:209–215PubMed
139.
Wilson NS, Dixit V, Ashkenazi A (2009) Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol 10:348–355PubMedCrossRef
140.
Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P (2007) RIP1, a kinase on the crossroads of a cell’s decision to live or die. Cell Death Differ 14:400–410PubMedCrossRef
141.
Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F et al (2011) The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 43:432–448PubMedCrossRef
142.
Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M et al (2010) Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 16:2443–2449PubMedCrossRef
143.
Butowski N, Chang SM, Lamborn KR, Polley MY, Parvataneni R, Hristova-Kazmierski M et al (2010) Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol 12:608–613PubMedCrossRef
144.
Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S et al (2010) Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res 70:490–500PubMedCrossRef
145.
Chin AI, Miyahira AK, Covarrubias A, Teague J, Guo B, Dempsey PW et al (2010) Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res 70:2595–2603PubMedCrossRef
146.
Rehli M (2002) Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 23:375–378PubMedCrossRef
147.
Lundberg AM, Drexler SK, Monaco C, Williams LM, Sacre SM, Feldmann M et al (2007) Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems. Blood 110:3245–3252PubMedCrossRef
148.
Heinz S, Haehnel V, Karaghiosoff M, Schwarzfischer L, Muller M, Krause SW et al (2003) Species-specific regulation of Toll-like receptor 3 genes in men and mice. J Biol Chem 278:21502–21509PubMedCrossRef
149.
Gowen BB, Wong MH, Jung KH, Sanders AB, Mitchell WM, Alexopoulou L et al (2007) TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not Poly(I:C): differential recognition of synthetic dsRNA molecules. J Immunol 178:5200–5208PubMed
150.
Jasani B, Navabi H, Adams M (2009) Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 27:3401–3404PubMedCrossRef
151.
Hoebe K, Janssen EM, Kim SO, Alexopoulou L, Flavell RA, Han J et al (2003) Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat Immunol 4:1223–1229PubMedCrossRef
152.
Datta SK, Redecke V, Prilliman KR, Takabayashi K, Corr M, Tallant T et al (2003) A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 170:4102–4110PubMed
153.
Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C et al (2009) Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 206:1589–1602PubMedCrossRef
154.
Fuertes Marraco SA, Scott CL, Bouillet P, Ives A, Masina S, Vremec D et al (2011) Type I interferon drives dendritic cell apoptosis via multiple BH3-only proteins following activation by PolyIC in vivo. PLoS One 6:e20189PubMedCrossRef
155.
McCartney S, Vermi W, Gilfillan S, Cella M, Murphy TL, Schreiber RD et al (2009) Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med 206:2967–2976PubMedCrossRef
156.
Perrot I, Deauvieau F, Massacrier C, Hughes N, Garrone P, Durand I et al (2010) TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA. J Immunol 185:2080–2088PubMedCrossRef
157.
Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L et al (2005) Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433:887–892PubMedCrossRef
158.
Wick DA, Martin SD, Nelson BH, Webb JR (2011) Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). Vaccine 29:984–993PubMedCrossRef
159.
Aranda F, Llopiz D, Diaz-Valdes N, Riezu-Boj JI, Bezunartea J, Ruiz M et al (2011) Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res 71:3214–3224PubMedCrossRef
160.
Salaun B, Greutert M, Romero P (2009) Toll-like receptor 3 is necessary for dsRNA adjuvant effects. Vaccine 27:1841–1847PubMedCrossRef
161.
Wang Y, Cella M, Gilfillan S, Colonna M (2010) Cutting edge: polyinosinic:polycytidylic acid boosts the generation of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in stromal cells. J Immunol 184:2751–2755PubMedCrossRef
162.
Pulko V, Liu X, Krco CJ, Harris KJ, Frigola X, Kwon ED et al (2009) TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J Immunol 183:3634–3641PubMedCrossRef
163.
Lin Q, Fang D, Fang J, Ren X, Yang X, Wen F et al (2011) Impaired wound healing with defective expression of chemokines and recruitment of myeloid cells in TLR3-deficient mice. J Immunol 186:3710–3717PubMedCrossRef
164.
Paone A, Galli R, Gabellini C, Lukashev D, Starace D, Gorlach A et al (2010) Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha. Neoplasia 12:539–549PubMed
165.
Zimmer S, Steinmetz M, Asdonk T, Motz I, Coch C, Hartmann E et al (2011) Activation of endothelial toll-like receptor 3 impairs endothelial function. Circ Res 108:1358–1366PubMedCrossRef
166.
Berge M, Bonnin P, Sulpice E, Vilar J, Allanic D, Silvestre JS et al (2010) Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am J Pathol 177:3192–3201PubMedCrossRef
167.
Chuang TH, Ulevitch RJ (2000) Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw 11:372–378PubMed
168.
Robbins SH, Walzer T, Dembele D, Thibault C, Defays A, Bessou G et al (2008) Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol 9:R17PubMedCrossRef
169.
Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL et al (2010) Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha + dendritic cells. J Exp Med 207:1261–1271PubMedCrossRef
170.
Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE et al (2010) Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 207:1247–1260PubMedCrossRef
171.
Hart OM, Athie-Morales V, O’Connor GM, Gardiner CM (2005) TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol 175:1636–1642PubMed
172.
Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S et al (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303:1526–1529PubMedCrossRef
173.
Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW et al (2004) Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 101:5598–5603PubMedCrossRef
174.
Forsbach A, Nemorin JG, Montino C, Muller C, Samulowitz U, Vicari AP et al (2008) Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol 180:3729–3738PubMed
175.
Demaria O, Pagni PP, Traub S, de Gassart A, Branzk N, Murphy AJ et al (2010) TLR8 deficiency leads to autoimmunity in mice. J Clin Invest 120:3651–3662PubMed
176.
Jurk M, Chikh G, Schulte B, Kritzler A, Richardt-Pargmann D, Lampron C et al (2011) Immunostimulatory potential of silencing RNAs can be mediated by a non-uridine-rich Toll-like receptor 7 motif. Nucleic Acid Ther 21(3):201–214
177.
Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S et al (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11:263–270PubMedCrossRef
178.
Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR (2003) Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5:834–839PubMedCrossRef
179.
Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ et al (2008) Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452:591–597PubMedCrossRef
180.
Lan T, Kandimalla ER, Yu D, Bhagat L, Li Y, Wang D et al (2007) Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proc Natl Acad Sci USA 104:13750–13755PubMedCrossRef
181.
Kandimalla ER, Struthers M, Bett AJ, Wisniewski T, Dubey SA, Jiang W et al (2011) Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists. Cell Immunol 270(2):126–134PubMedCrossRef
182.
Wang D, Precopio M, Lan T, Yu D, Tang JX, Kandimalla ER et al (2010) Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8. Mol Cancer Ther 9:1788–1797PubMedCrossRef
183.
Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M (2004) Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50:722–733PubMedCrossRef
184.
Bong AB, Bonnekoh B, Franke I, Schon MP, Ulrich J, Gollnick H (2002) Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 205:135–138PubMedCrossRef
185.
Turza K, Dengel LT, Harris RC, Patterson JW, White K, Grosh WW et al (2010) Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. J Cutan Pathol 37:94–98PubMedCrossRef
186.
Wolf IH, Cerroni L, Kodama K, Kerl H (2005) Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 141:510–514PubMedCrossRef
187.
Wolf IH, Smolle J, Binder B, Cerroni L, Richtig E, Kerl H (2003) Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 139:273–276PubMedCrossRef
188.
Hirsch I, Caux C, Hasan U, Bendriss-Vermare N, Olive D (2010) Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends Immunol 31:391–397PubMedCrossRef
189.
Dudek AZ, Yunis C, Harrison LI, Kumar S, Hawkinson R, Cooley S et al (2007) First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 13:7119–7125PubMedCrossRef
190.
Dummer R, Hauschild A, Becker JC, Grob JJ, Schadendorf D, Tebbs V et al (2008) An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res 14:856–864PubMedCrossRef
191.
Inglefield JR, Dumitru CD, Alkan SS, Gibson SJ, Lipson KE, Tomai MA et al (2008) TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. J Interferon Cytokine Res 28:253–263PubMedCrossRef
192.
Cohen P, Northfelt D, Weiss GJ, Von Hoff DD, Manjarrez K, Ditesch G et al (2011) Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) agonist, in patients with advanced solid tumors. J Clin Oncol 29:2537CrossRef
193.
Bourquin C, Hotz C, Noerenberg D, Voelkl A, Heidegger S, Roetzer LC et al (2011) Systemic cancer therapy with a small molecule agonist of Toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Res 71:5123–5133PubMedCrossRef
194.
Lu H, Wagner WM, Gad E, Yang Y, Duan H, Amon LM et al (2010) Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol 184:5360–5367PubMedCrossRef
195.
Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M (2004) Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 173:3051–3061PubMed
196.
Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G (2007) Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 204:1441–1451PubMedCrossRef
197.
Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X et al (2005) Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 174:1259–1268PubMed
198.
Gorski KS, Waller EL, Bjornton-Severson J, Hanten JA, Riter CL, Kieper WC et al (2006) Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol 18:1115–1126PubMedCrossRef
199.
Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T et al (2005) Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 309:1380–1384PubMedCrossRef
200.
Cherfils-Vicini J, Platonova S, Gillard M, Laurans L, Validire P, Caliandro R et al (2010) Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 120:1285–1297PubMedCrossRef
201.
Spranger S, Javorovic M, Burdek M, Wilde S, Mosetter B, Tippmer S et al (2010) Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol 185:738–747PubMedCrossRef
202.
Pufnock JS, Cigal M, Rolczynski LS, Andersen-Nissen E, Wolfl M, McElrath MJ et al (2011) Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28. Blood 117:6542–6551PubMedCrossRef
203.
Zobywalski A, Javorovic M, Frankenberger B, Pohla H, Kremmer E, Bigalke I et al (2007) Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med 5:18PubMedCrossRef
204.
Shackleton M, Davis ID, Hopkins W, Jackson H, Dimopoulos N, Tai T et al (2004) The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun 4:9PubMed
205.
Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R et al (2006) The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 176:157–164PubMed
206.
Ma F, Zhang J, Zhang J, Zhang C (2010) The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell Mol Immunol 7:381–388PubMedCrossRef
207.
Mahnke K, Qian Y, Fondel S, Brueck J, Becker C, Enk AH (2005) Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res 65:7007–7012PubMedCrossRef
208.
Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM (2002) Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196:1627–1638PubMedCrossRef
209.
Adams S, O’Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K et al (2008) Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 181:776–784PubMed
210.
Edwards AD, Diebold SS, Slack EM, Tomizawa H, Hemmi H, Kaisho T et al (2003) Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol 33:827–833PubMedCrossRef
211.
Pedersen G, Andresen L, Matthiessen MW, Rask-Madsen J, Brynskov J (2005) Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium. Clin Exp Immunol 141:298–306PubMedCrossRef
212.
Platz J, Beisswenger C, Dalpke A, Koczulla R, Pinkenburg O, Vogelmeier C et al (2004) Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J Immunol 173:1219–1223PubMed
213.
Lebre MC, van der Aar AM, van Baarsen L, van Capel TM, Schuitemaker JH, Kapsenberg ML et al (2007) Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol 127:331–341PubMedCrossRef
214.
Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H et al (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408:740–745PubMedCrossRef
215.
Copin R, De BP, Carlier Y, Letesson JJ, Muraille E (2007) MyD88-dependent activation of B220-CD11b+LY-6C+ dendritic cells during Brucella melitensis infection. J Immunol 178:5182–5191PubMed
216.
Lee KS, Scanga CA, Bachelder EM, Chen Q, Snapper CM (2007) TLR2 synergizes with both TLR4 and TLR9 for induction of the MyD88-dependent splenic cytokine and chemokine response to Streptococcus pneumoniae. Cell Immunol 245:103–110PubMedCrossRef
217.
Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, Sher A (2005) TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med 202:1715–1724PubMedCrossRef
218.
Anderson AE, Worku ML, Khamri W, Bamford KB, Walker MM, Thursz MR (2007) TLR9 polymorphisms determine murine lymphocyte responses to Helicobacter: results from a genome-wide scan. Eur J Immunol 37:1548–1561PubMedCrossRef
219.
Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A (2003) Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 198:513–520PubMedCrossRef
220.
Sasai M, Linehan MM, Iwasaki A (2010) Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3. Science 329:1530–1534PubMedCrossRef
221.
Krug A, French AR, Barchet W, Fischer JA, Dzionek A, Pingel JT et al (2004) TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 21:107–119PubMedCrossRef
222.
Zhu J, Huang X, Yang Y (2007) Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol 81:3170–3180PubMedCrossRef
223.
Fathallah I, Parroche P, Gruffat H, Zannetti C, Johansson H, Yue J et al (2010) EBV latent membrane protein 1 is a negative regulator of TLR9. J Immunol 185:6439–6447PubMedCrossRef
224.
Andersen JM, Al-Khairy D, Ingalls RR (2006) Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens. Biol Reprod 74:824–831PubMedCrossRef
225.
Kandimalla ER, Bhagat L, Li Y, Yu D, Wang D, Cong YP et al (2005) Immunomodulatory oligonucleotides containing a cytosine-phosphate-2′-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists. Proc Natl Acad Sci USA 102:6925–6930PubMedCrossRef
226.
Wakefield D, Gray P, Chang J, Di GN, McCluskey P (2010) The role of PAMPs and DAMPs in the pathogenesis of acute and recurrent anterior uveitis. Br J Ophthalmol 94:271–274PubMedCrossRef
227.
Rubartelli A, Lotze MT (2007) Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 28:429–436PubMedCrossRef
228.
Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P (2010) Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 1805:53–71PubMed
229.
Carta S, Castellani P, Delfino L, Tassi S, Vene R, Rubartelli A (2009) DAMPs and inflammatory processes: the role of redox in the different outcomes. J Leukoc Biol 86:549–555PubMedCrossRef
230.
Gilliet M, Lande R (2008) Antimicrobial peptides and self-DNA in autoimmune skin inflammation. Curr Opin Immunol 20:401–407PubMedCrossRef
231.
Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M et al (2004) Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 34:251–262PubMedCrossRef
232.
Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R et al (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546–549PubMedCrossRef
233.
Brinkmann MM, Spooner E, Hoebe K, Beutler B, Ploegh HL, Kim YM (2007) The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. J Cell Biol 177:265–275PubMedCrossRef
234.
Tabeta K, Hoebe K, Janssen EM, Du X, Georgel P, Crozat K et al (2006) The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol 7:156–164PubMedCrossRef
235.
Kim YM, Brinkmann MM, Paquet ME, Ploegh HL (2008) UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature 452:234–238PubMedCrossRef
236.
Sepulveda FE, Maschalidi S, Colisson R, Heslop L, Ghirelli C, Sakka E et al (2009) Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity 31:737–748PubMedCrossRef
237.
Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi GP, Chapman HA et al (2008) The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 456:658–662PubMedCrossRef
238.
Park B, Brinkmann MM, Spooner E, Lee CC, Kim YM, Ploegh HL (2008) Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat Immunol 9:1407–1414PubMedCrossRef
239.
Ewald SE, Engel A, Lee J, Wang M, Bogyo M, Barton GM (2011) Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. J Exp Med 208:643–651PubMedCrossRef
240.
Kemp TJ, Elzey BD, Griffith TS (2003) Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J Immunol 171:212–218PubMed
241.
Bekeredjian-Ding I, Jego G (2009) Toll-like receptors—sentries in the B-cell response. Immunology 128:311–323PubMedCrossRef
242.
Hanten JA, Vasilakos JP, Riter CL, Neys L, Lipson KE, Alkan SS et al (2008) Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol 9:39PubMedCrossRef
243.
Bernasconi NL, Traggiai E, Lanzavecchia A (2002) Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298:2199–2202PubMedCrossRef
244.
Eckl-Dorna J, Batista FD (2009) BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. Blood 113:3969–3977PubMedCrossRef
245.
Holtick U, Scheulen ME, von Bergwelt-Baildon MS, Weihrauch MR (2011) Toll-like receptor 9 agonists as cancer therapeutics. Expert Opin Investig Drugs 20:361–372PubMedCrossRef
246.
Goodchild A, Nopper N, Craddock A, Law T, King A, Fanning G et al (2009) Primary leukocyte screens for innate immune agonists. J Biomol Screen 14:723–730PubMedCrossRef
247.
Agrawal S, Kandimalla ER (2007) Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans 35:1461–1467PubMedCrossRef
248.
Krieg AM (2008) Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27:161–167PubMedCrossRef
249.
250.
van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ et al (2003) CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res 63:5595–5600PubMed
251.
Schmidt C (2007) Clinical setbacks for toll-like receptor 9 agonists in cancer. Nat Biotechnol 25:825–826PubMedCrossRef
252.
Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH et al (2010) In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 28:4324–4332PubMedCrossRef
253.
Kochling J, Prada J, Bahrami M, Stripecke R, Seeger K, Henze G et al (2008) Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. Vaccine 26:4669–4675PubMedCrossRef
254.
Vaisanen MR, Vaisanen T, Jukkola-Vuorinen A, Vuopala KS, Desmond R, Selander KS et al (2010) Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. Prostate 70:817–824PubMedCrossRef
255.
Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez LO, del Casar JM, Lamelas ML et al (2010) Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 10:665PubMedCrossRef
256.
Kuninaka N, Kurata M, Yamamoto K, Suzuki S, Umeda S, Kirimura S et al (2010) Expression of Toll-like receptor 9 in bone marrow cells of myelodysplastic syndromes is down-regulated during transformation to overt leukemia. Exp Mol Pathol 88:293–298PubMedCrossRef
257.
Daud II, Scott ME, Ma Y, Shiboski S, Farhat S, Moscicki AB (2011) Association between toll-like receptor expression and human papillomavirus type 16 persistence. Int J Cancer 128:879–886PubMedCrossRef
258.
Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G (2008) Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood 112:2205–2213PubMedCrossRef
259.
Yu L, Chen S (2008) Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother 57:1271–1278PubMedCrossRef
260.
Gekeler V, Gimmnich P, Hofmann HP, Grebe C, Rommele M, Leja A et al (2006) G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides 16:83–93PubMedCrossRef
261.
Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R (2006) Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther 5:1585–1592PubMedCrossRef
262.
Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW et al (2007) Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 67:774–781PubMedCrossRef
263.
El AA, Sonabend AM, Han Y, Lesniak MS (2006) Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 54:526–535CrossRef
264.
Fischer SF, Rehm M, Bauer A, Hofling F, Kirschnek S, Rutz M et al (2005) Toll-like receptor 9 signaling can sensitize fibroblasts for apoptosis. Immunol Lett 97:115–122PubMedCrossRef
265.
Jozsef L, Khreiss T, Filep JG (2004) CpG motifs in bacterial DNA delay apoptosis of neutrophil granulocytes. FASEB J 18:1776–1778PubMed
266.
Chang YJ, Wu MS, Lin JT, Chen CC (2005) Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol 175:8242–8252PubMed
267.
Damiano V, Caputo R, Bianco R, D’Armiento FP, Leonardi A, De PS et al (2006) Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res 12:577–583PubMedCrossRef
268.
Nierkens S, den Brok MH, Garcia Z, Togher S, Wagenaars J, Wassink M et al (2011) Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res 71(20):6428–6437PubMedCrossRef
269.
Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A et al (2011) Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 71:5423PubMedCrossRef
270.
Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B et al (2003) Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 63:6478–6487PubMed
271.
Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, Pacheco Y et al (2007) Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 178:2763–2769PubMed
272.
Dolganiuc A, Chang S, Kodys K, Mandrekar P, Bakis G, Cormier M et al (2006) Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol 177:6758–6768PubMed
273.
Conry SJ, Milkovich KA, Yonkers NL, Rodriguez B, Bernstein HB, Asaad R et al (2009) Impaired plasmacytoid dendritic cell (PDC)-NK cell activity in viremic human immunodeficiency virus infection attributable to impairments in both PDC and NK cell function. J Virol 83:11175–11187PubMedCrossRef
274.
Ulsenheimer A, Gerlach JT, Jung MC, Gruener N, Wachtler M, Backmund M et al (2005) Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology 41:643–651PubMedCrossRef
275.
Kang DC, Gopalkrishnan RV, Lin L, Randolph A, Valerie K, Pestka S et al (2004) Expression analysis and genomic characterization of human melanoma differentiation associated gene-5, mda-5: a novel type I interferon-responsive apoptosis-inducing gene. Oncogene 23:1789–1800PubMedCrossRef
276.
Kovacsovics M, Martinon F, Micheau O, Bodmer JL, Hofmann K, Tschopp J (2002) Overexpression of Helicard, a CARD-containing helicase cleaved during apoptosis, accelerates DNA degradation. Curr Biol 12:838–843PubMedCrossRef
277.
Tormo D, Checinska A, Alonso-Curbelo D, Perez-Guijarro E, Canon E, Riveiro-Falkenbach E et al (2009) Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell 16:103–114PubMedCrossRef
278.
Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS et al (2008) 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 14:1256–1263PubMedCrossRef
279.
Besch R, Poeck H, Hohenauer T, Senft D, Hacker G, Berking C et al (2009) Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest 119:2399–2411PubMed
280.
Kubler K, Pesch CT, Gehrke N, Riemann S, Dassler J, Coch C et al (2011) Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly(I:C) leads to myeloid cell maturation and activates NK cells. Eur J Immunol 41(10):3028–3039PubMedCrossRef
281.
Liu TX, Zhang JW, Tao J, Zhang RB, Zhang QH, Zhao CJ et al (2000) Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood 96:1496–1504PubMed
282.
Jiang LJ, Zhang NN, Ding F, Li XY, Chen L, Zhang HX et al (2011) RA-inducible gene-I induction augments STAT1 activation to inhibit leukemia cell proliferation. Proc Natl Acad Sci USA 108:1897–1902PubMedCrossRef
Metadata
Title
Targeting pattern recognition receptors in cancer immunotherapy
Authors
Nadège Goutagny
Yann Estornes
Uzma Hasan
Serge Lebecque
Christophe Caux
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Targeted Oncology / Issue 1/2012
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-012-0213-1

Other articles of this Issue 1/2012

Targeted Oncology 1/2012 Go to the issue

Review

Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival

Review

Advancement in the research on vascular endothelial growth inhibitor (VEGI)

Editorial

Recent successes of cancer immunotherapy: a new dimension in personalized medicine?

Review

Targeting regulatory T cells

Review

Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility?

Review

A review on various targeted anticancer therapies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits